Nurem Medical has raised RMB 800 million (USD 112 million) in Series D financing led by SCGC Capital and PICC Capital, with participation from multiple institutional investors. The China-based company operates a proprietary radiopharmaceutical platform, with exports to Southeast Asia and including China's first commercial 30MeV IKON proton accelerator, enabling domestic production of germanium-68 and actinium-225 isotopes. Nurem's pipeline features four clinical-stage candidates including Phase III hepatocellular carcinoma (HCC) therapy NRT6003 and Phase I/II pancreatic cancer treatment NRT6008.

The funding accelerates radiopharmaceutical commercialisation, addressing import dependency for medical isotopes with applications in liver, pancreatic and prostate cancers. Nurem's capabilities cover isotope production, drug development and CDMO services, positioning China for global radiopharmaceutical supply chain participation.

PharmCube's NextBiopharm® database lists over 70 developers of actinium-225-based drugs globally. Click here to request a free trial for NextBiopharm®.